October 28, 2016 3:53 PM ET

Healthcare Equipment and Supplies

Company Overview of Metamark Genetics, Inc.

Company Overview

Metamark Genetics, Inc. develops diagnostic and prognostic tests for urology cancer care. It offers ProMark, a protein based prognostic test for prostate cancer; and Progensa, a urine-based molecular test to make informed repeat biopsy decisions. The company also provides cytology diagnostic services for diagnosis of bladder cancer; luorescence in situ hybridization, a diagnostic tool that helps to confirm patient’s cytology results; histology diagnostic services for prostate and bladder biopsy analysis and examinations; and PTEN/ERG molecular testing that predicts aggressiveness of HGPIN/atypical or low gleason score. It offers services in the areas of diagnosis and management of prostate c...

245 First Street

10th Floor

Cambridge, MA 02142

United States

Founded in 2007





Key Executives for Metamark Genetics, Inc.

Chief Executive Officer, President and Director
Age: 53
Co-Founder and Chairman
Age: 78
Co-Founder, Director and Scientific & Clinical Advisor
Age: 73
Co-Founder and Scientific & Clinical Advisor
Chief Science Officer and Senior Vice President
Compensation as of Fiscal Year 2016.

Metamark Genetics, Inc. Key Developments

Metamark Genetics, Inc. Announces Agreement with Blue Cross and Blue Shield of Texas

Metamark Genetics, Inc. announced that effective June 1, 2016, the company signed an agreement with Blue Cross and Blue Shield of Texas to provide its members with in-network access to Metamark's offering of urology specialized diagnostics. Metamark has previously announced in-network agreements with additional large Blue Cross and Blue Shield Plans and also has agreements in place with the PPO networks in the country.

Metamark Genetics, Inc. Announces Agreement with Anthem Blue Cross Blue Shield of Georgia

Metamark Genetics, Inc. announced that effective May 25, 2016, the company has signed an agreement with Anthem Blue Cross Blue Shield (BCBS) of Georgia to provide its members with in-network access to Metamark's comprehensive suite of urology specialized diagnostic offerings.

Metamark Genetics, Inc. Announces Management Changes

Metamark Genetics, Inc. announced that Jerry Williamson has been named as the company's new President, Chief Executive Officer, and Director. Mr. Williamson succeeds Ken Weg, who will retain an active role as Chairman of Metamark's Board of Directors. Mr. Williamson joined Metamark in 2015 as Chief Commercial Officer. Prior to Metamark, Mr. Williamson was a Partner with Ventures focused on building and developing relationships with corporate partners for the firm's core innovation and investment activities. He served as Vice President and General Manager for Molecular Devices. Mr. Williamson was President of Global Commercial Operations for Genetix Ltd. and served as President of Biacore, Inc.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Metamark Genetics, Inc., please visit www.metamarkgenetics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.